Back to Search Start Over

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER

Authors :
S. V. MISHUGIN
A. A. GRITSKEVICH
I. G. RUSAKOV
Source :
Медицинский совет, Vol 0, Iss 10, Pp 34-37 (2016)
Publication Year :
2016
Publisher :
Remedium Group LLC, 2016.

Abstract

Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice. There have been discovered several generations of the antiandrogens over the years and the possibility of using these drugs in clinical practice has significantly changed. First generations of the antiandrogens (cyproterone, flutamid, bicalutamid) are used mainly for the treatment of advanced hormonsensitive PCa in combination with castration therapy. However these drugs do not increase survival in patients with PCa and are not indicated in terms of castration resistant PCa. Discovery of the enzalutamide (antiandrogen of 2’d generation), acting on the nuclear level of the tumor cell, allowed to increase significantly survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and improve treatment results in patients with mCRPC. At the moment enzalutamide is being studied in combination with castration therapy in patients with hormonsensitive PCa.

Details

Language :
Russian
ISSN :
2079701X and 26585790
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Медицинский совет
Publication Type :
Academic Journal
Accession number :
edsdoj.336ae36df4d01be13a8184eb76018
Document Type :
article
Full Text :
https://doi.org/10.21518/2079-701X-2016-10-34-37